Zolpidem Orifarm

Quick links

Choose a section

Quick links to important sections

Advertisements

Zolpidem Orifarm

Advertisements
Advertisements

Treatment option: Insomnia, Polysomnography

Advertisements

Overview of Zolpidem Orifarm

Quick Facts

Property Description
Active ingredient Zolpidem (as Zolpidem tartrate)
Form Oral Tablet (Immediate-release or Extended-release)
Pharmacological class Sedative-Hypnotic; Nonbenzodiazepine (Z-drug)
Common use Aid for sleep initiation (falling asleep)
Origin Synthetic Organic Compound

What Type of Medicine is Zolpidem Orifarm?

Zolpidem Orifarm is a prescription medication utilized in adults for the short-term treatment of insomnia, specifically addressing difficulties with sleep initiation. The active compound, Zolpidem, is classified as a sedative-hypnotic agent and belongs to the imidazopyridine chemical class, recognized as a nonbenzodiazepine or Z-drug. This medicine is a central nervous system (CNS) depressant, a property that is clinically recognized for prioritizing the hypnotic effect. Zolpidem is used for disorders of the nervous system, including sleep disorders, and is recognized as an agent acting on the central nervous system to treat sleep-related issues.

The Active Ingredient and Pharmaceutical Form

Zolpidem Orifarm is a single active ingredient product, typically containing the salt Zolpidem tartrate, which is a synthetic organic compound. The specific brand Orifarm usually denotes a generic or parallel-imported product, positioning it as an established, cost-effective alternative to originator brands. The preparation is most commonly administered via the oral route in the form of a tablet, although alternative formulations, such as sublingual tablets, are also available. Zolpidem functions as a GABA-A receptor agonist, enhancing inhibitory neurotransmission to promote sedation. This mechanism functions to boost the brain's natural calming processes.

How Does Zolpidem Help with Sleep Initiation?

The core action of Zolpidem is achieved through its selective ability to enhance the effects of the inhibitory chemical GABA (gamma-aminobutyric acid) within the brain. By selectively boosting this internal "slow-down" signal, the drug rapidly reduces the excessive neuronal activity that prevents sleep. This process directly and effectively shortens the time it takes for a patient to fall asleep.

Advertisements

What side effects are possible with Zolpidem Orifarm?

Possible Side Effects and Safety Information

The safety profile for Zolpidem is officially documented based on frequency and the body system affected, reflecting its primary function as a central nervous system (CNS) depressant. These adverse reactions are categorized according to regulatory standards (e.g., Common, Uncommon, Rare) found in official prescribing information.

Commonly Documented Adverse Reactions

Adverse reactions classified as Common (occurring in at least 1 in 100 users) typically involve the nervous system and the gastrointestinal tract. These reactions include somnolence (drowsiness), headache, dizziness, and diarrhoea. Effects classified as Uncommon include hallucinations, agitation, and anterograde amnesia (memory loss).

Serious Adverse Reactions and Constraints

Regulatory documents identify specific risks that require clear attention. These include the occurrence of Complex Sleep Behaviors, such as sleep-walking, sleep-driving, and other activities performed while not fully awake, which may result in serious injury. Additionally, rare, severe hypersensitivity reactions, like Angioedema (swelling of the face, tongue, or throat), have been documented. The drug is formally Contraindicated in individuals with severe hepatic impairment.

Time-Related Safety and Vulnerable Populations

The risk of developing Tolerance and both physical and psychological Dependence is noted to increase with the duration of treatment. A particular focus is placed on the Older Adult population, who are recognized to have an increased susceptibility to falls and subsequent severe injuries dueable to the sedative effects. The potential for next-day impairment, such as psychomotor slowing, is emphasized if insufficient time for sleep (less than 8 hours) remains after ingestion.

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Severity

Official regulatory documents state that Zolpidem overdose primarily results in symptoms of exaggerated Central Nervous System (CNS) depression. Manifestations may range from somnolence and confusion to a profound light coma. Physiologically, overdose can lead to respiratory depression and hypotension (low blood pressure).

The most severe outcomes documented in official labeling include cardiorespiratory collapse and a fatal outcome, with risk substantially increased when Zolpidem is taken with alcohol or other CNS depressant agents (poly-drug overdose). The official labeling also notes that the elderly and individuals with hepatic insufficiency may be especially sensitive to adverse overdose effects.

When to Seek Immediate Help

Due to the documented risk of severe or life-threatening compromise, regulatory authorities explicitly instruct users to seek immediate medical attention or call a Poison Control Center immediately if an overdose is suspected.

Management and Monitoring

Overdose management, as officially described, focuses on general symptomatic and supportive treatment. Procedural options may include gastric lavage and the administration of activated charcoal where medically appropriate. The benzodiazepine antagonist Flumazenil is documented in regulatory sources as an intervention that may reverse the sedative effects, though its use is guided by clinical context. Close monitoring of the patient's respiratory and cardiovascular status is required.

Advertisements

Therapeutic Uses of Zolpidem Orifarm

What Zolpidem Orifarm Treats: Main Uses and Benefits

Zolpidem Orifarm is commonly used for the short-term management of insomnia in adults, primarily addressing difficulties with sleep initiation. The primary therapeutic benefit is associated with a reduction in the time required to fall asleep, which may help support a more stable start to the rest cycle. It is relevant for situations where the inability to initiate sleep is severe or debilitating.

The medication may also assist with easing symptom clusters related to fragmented sleep, such as nocturnal awakenings followed by difficulty returning to rest. This supportive use is applicable in contexts marked by acute or episodic disturbances. It helps ease the overall symptom load and may contribute to supporting general well-being during periods of heightened discomfort. It is used for managing symptoms of sleep-onset insomnia, addressing recurrent episodic disturbances, and easing fragmented sleep related to temporary stressors.


Quick Fact Relief for Symptomatic Sleep Deficits
Primary Symptom Targeted Difficulty falling asleep (Sleep onset latency)
Nature of Use Short-term symptomatic assistance
Core Benefit May support a reduction in the time required to fall asleep
Advertisements

Eligibility and Restrictions for Use

Zolpidem Orifarm is regulated for use only within specific population groups and is strictly prohibited or restricted for others, based on official regulatory labeling.

Eligibility Scope

Eligibility Status Population Group Regulatory Basis
Permitted Use Adults (18 years and older) Designated for the short-term treatment of insomnia.
Not Recommended Children and Adolescents (under 18 years) Safety and effectiveness have not been established.
Conditional Use Older Adults (Geriatric) Requires caution and a mandatory lower initial dose due to increased sensitivity.
Conditional Use Mild to Moderate Hepatic Impairment Requires caution and a mandatory reduced initial dose.
Not Recommended Pregnancy and Lactation Contraindicated in the third trimester of pregnancy. Not recommended while breastfeeding.

Absolute Contraindications

Use of Zolpidem Orifarm is strictly prohibited in patients with certain conditions, as defined in official regulatory documents:

  • Hypersensitivity to zolpidem or any excipients.
  • Severe Hepatic Insufficiency.
  • Myasthenia Gravis.
  • Severe Sleep Apnoea Syndrome or Acute/Severe Pulmonary Insufficiency.
  • A history of complex sleep behaviors (such as sleep-driving or walking) after taking zolpidem.

Use also requires caution in patients with a history of drug or alcohol abuse or existing psychiatric conditions.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information for Zolpidem Orifarm


Interaction Scope

Category Official Regulatory Documentation Summary
Medicinal product categories with documented interactions Central Nervous System (CNS) Depressants, Opioids, CYP3A4 Inducers, CYP3A4 Inhibitors.
Specific interacting medicines (if explicitly listed) Rifampin, Ketoconazole, Imipramine, Chlorpromazine, St. John's wort.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic: Alteration of metabolism primarily via CYP3A4 enzymes. Pharmacodynamic: Additive CNS depressant effects.
Timing-based interaction rules (if applicable) Administration and Alertness: A period of at least 7 to 8 hours is required between intake and activities requiring mental alertness. Food: Ingestion with a meal may slow the onset of effect.
Population-specific interaction notes (if applicable) Severe Hepatic Impairment: Contraindicated due to risk of reduced clearance leading to excessive exposure.
Interaction-related restrictions Alcohol (Ethanol): Co-administration is formally contraindicated. Opioids: Concomitant prescribing is restricted to where alternative treatments are not possible.

Interaction Classifications (High-Level)

Category Official Regulatory Documentation Summary
Interaction severity classification (as defined in official documents) Contraindicated (e.g., Alcohol, Severe Hepatic Impairment), Increased Exposure/Effect, Decreased Exposure/Effect, Additive Adverse Effects.
Regulatory basis (EMA / FDA / etc.) Based on documented findings in the Summary of Product Characteristics (SmPC) and FDA Prescribing Information.
Interaction-context constraints (as defined in official documents) Food: Delays onset. Activities: Requires 7–8 hour separation.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Alcohol is contraindicated due to the potential for additive psychomotor impairment and increased risk of complex sleep behaviors.
  • Concomitant use with Opioids and other CNS Depressants carries a risk of additive CNS depression, including profound sedation and respiratory compromise.
  • Ketoconazole (a strong CYP3A4 inhibitor) is documented to increase exposure to zolpidem, while Rifampin (a strong CYP3A4 inducer) is documented to decrease exposure and clinical effect.
  • The regulatory label requires a separation of at least 7 to 8 hours between taking the dose and performing activities requiring mental alertness.
  • The product is formally contraindicated in patients with severe hepatic impairment due to a reduced capacity for drug clearance.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define this product's interaction structure primarily through its susceptibility to two documented effects: Pharmacodynamic reinforcement with other CNS depressants, which dictates contraindications and restrictions, and Pharmacokinetic susceptibility to CYP3A4 enzyme modification, which classifies interacting medicines by their ability to significantly increase or decrease drug exposure. This dual structure outlines explicit constraints on co-administration timing and substance combination.

Advertisements

Mechanism of Action

How Zolpidem Orifarm Works

Targeted Modulation of GABA A Receptors

This compound functions as a Positive Allosteric Modulator that acts selectively on a specific subset of GABA A receptor complexes, primarily those containing the alpha1 subunit. This interaction enhances the receptor's sensitivity to the major inhibitory neurotransmitter, gamma-aminobutyric acid ( GABA), which is the foundational molecular step in the drug's mechanism.


Enhancing Central Inhibitory Neurotransmission

By augmenting the effect of GABA, the compound intensifies activity within the central inhibitory neurotransmission pathway. This increased inhibitory signaling drives a flow of negative chloride ions into the neuron. The resulting hyperpolarization decreases the membrane potential, consequently reducing neuronal excitability across the central nervous system.


Resulting Physiological State

The cellular cascade leads to a systemic dampening of arousal circuits and a reduction in overall brain activity. This fundamental change in neural excitability diminishes the communication of nerve cells in regions governing alertness, which is the key physiological change resulting in a state of central nervous system depression and producing the sedative state.

Advertisements

Dosage and Administration Information

How to Use Zolpidem Orifarm

Zolpidem Orifarm is administered via the oral route as a single dose immediately before going to bed. This administration must occur only when the user is prepared to sleep and has a minimum of 7 to 8 hours available before the planned time of awakening. The dose is typically swallowed whole with fluid; Extended-Release tablets must not be crushed, divided, or chewed to preserve their release mechanism.

Official Dosing Regimens and Adjustments

Official dosing is designed for short-term use, generally for a few days up to a maximum of four weeks, including any necessary gradual dose reduction. The single maximum daily dose is 10 mg for Immediate-Release tablets and 12.5 mg for Extended-Release tablets.

Specific dosage adjustments are recommended for certain populations:

  • Older Adults and Patients with Mild Hepatic Impairment: The recommended starting and maximum daily dose is reduced to 5 mg (IR) or 6.25 mg (ER).
  • Sex-Specific Initiation: For Immediate-Release tablets, the initial dose is 5 mg for women and 5 mg or 10 mg for men; a lower dose is recommended for women due to slower drug clearance.

If a dose is missed and less than 7 hours of sleep time remains, the dose should not be taken.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Zolpidem Orifarm

Evidence for Difficulties Falling Asleep (Sleep Initiation)

Zolpidem was studied for individuals with difficulties initiating sleep (sleep-onset insomnia). Short-term, placebo-controlled randomized controlled trials (RCTs) are the dominant study type. These studies typically involved adult populations who were diagnosed with primary insomnia. Researchers examined how long it took participants to fall asleep using objective measurements taken in a sleep lab, such as Polysomnography (PSG), as well as subjective data reported by patients in daily sleep diaries.

The findings from these core studies describe the evolution of the measured time required to fall asleep over the study period. Regulatory reviews of this body of evidence consistently indicate that this area of research is the most robust, with a classification of High level of evidence available from numerous, well-designed trials.

However, the majority of the existing data focuses on short-term outcomes, usually lasting only two to four weeks. This limits the insight into how symptoms evolve after many months of continuous administration. Furthermore, data for certain groups, such as younger adolescents, remain insufficient, and findings describe group patterns, not personal outcomes.


Evidence for Difficulties Staying Asleep (Sleep Maintenance)

Research examined outcomes related to sleep continuity, which focuses on the ability to maintain sleep through the night. These studies monitored outcomes related to functional imbalance, including Total Sleep Time (TST) and the duration of time spent awake after initially falling asleep (Wake After Sleep Onset). This research involved RCTs, often using these maintenance measures as secondary endpoints.

Studies report how total sleep time and the frequency of nocturnal awakenings evolved in the observed populations, sometimes utilizing specialized formulations designed to monitor outcomes over defined time intervals. While research highlights changes measured during the study period, the findings for these maintenance outcomes have been mixed or less universally consistent than the data for sleep initiation. The evidence quality varies across studies, leading this research area to be classified as Moderate.


Long-Term Studies and Extended Follow-up

While the primary research and regulatory focus on short-term use, some studies have been conducted to monitor outcomes related to Zolpidem over extended time intervals. These longitudinal investigations have tracked measured outcomes related to sleep initiation and maintenance for periods ranging up to 12 weeks, and in some cases, up to 8 months or 12 months of use.

However, long-term effects are not fully established and remain an area of uncertainty. Data are still emerging, and there is limited information concerning the stability of the observed sleep patterns and patient-reported experiences beyond the duration of the core clinical trials.


Evidence in Special Populations

Research dedicated to Older Adults (individuals age 65 and over) has been conducted. These studies examined patient-reported experiences related to sleep and monitored symptom evolution over defined time intervals.

The findings describe group patterns observed in the specific populations studied, meaning they cannot be assumed to apply directly to other groups, such as pregnant populations or those with specific chronic comorbidities not included in the main trials. Data for certain groups remain insufficient for broad conclusions.


What is Still Uncertain About the Research

The existing research, while extensive, provides context but not individual predictions, and highlights areas where data are still limited.

  • The evidence base is most robust for short-term use and less so for chronic, long-term administration, where long-term effects are not fully established.
  • Regulatory reviews have described that a limitation noted in research concerns residual effects on alertness and daily functioning observed the day after administration.
  • The research mainly describes group patterns, and findings for certain secondary outcomes, like Total Sleep Time, were sometimes mixed or less consistent than the data for sleep initiation.
  • Subgroup findings are uncertain or lacking for many populations, and the results reflect the specific conditions under which the core studies were conducted.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Zolpidem Orifarm (FAQ)

Q: Can I stop taking Zolpidem Orifarm suddenly, or should I taper the dose?

A: According to the official product information, treatment should be considered for gradual withdrawal by slowly reducing the dose. Stopping suddenly may increase the risk of rebound insomnia, which is when the original sleep problem returns, possibly worse than before. Regulatory documents suggest that a slow reduction may help mitigate withdrawal symptoms and support the safest cessation process.


Q: What is the typical duration for using Zolpidem Orifarm?

A: Regulatory documents indicate that treatment with Zolpidem Orifarm should be as short as possible. The recommended maximum duration for use is generally four weeks, and this period includes the time required for gradual dose reduction. The official product information stresses that continuous long-term use is not recommended due to the potential for dependency.


Q: Does Zolpidem Orifarm cause physical or psychological dependence?

A: Studies and official information indicate that using Zolpidem Orifarm carries a risk of dependence, which can be physical or psychological. This risk is officially noted to increase with higher doses and longer durations of treatment. Patients with a history of alcohol or drug abuse are also stated to be at a greater risk of developing this dependence.


Q: Is Zolpidem Orifarm the only treatment for insomnia?

A: According to the official product information, Zolpidem Orifarm is specifically used to treat short-term insomnia in adults. Regulatory documents state that the cause of sleep disturbance should be investigated before prescribing, indicating a broader consideration of treatment approaches beyond medication for chronic sleep issues.


Q: Can I use Zolpidem Orifarm for jet lag?

A: Official regulatory documents state that Zolpidem Orifarm is indicated only for the treatment of insomnia that is severe, disabling, or causing extreme distress in adults. Regulatory labeling specifies the indication only for these severe forms, and does not authorize use for temporary sleep disruptions like jet lag or minor sleep issues.


Q: What is the mechanism of action of Zolpidem Orifarm? How does it help sleep?

A: Zolpidem belongs to a group of medicines called GABA-A receptor agonists. According to official sources, it works by binding to certain sites on GABA receptors in the brain. This action is known to enhance the effects of a natural calming chemical called GABA, which helps slow down brain activity and induce sleep.

Advertisements

How should Zolpidem Orifarm be stored and disposed of?

Official Storage and Disposal Requirements

Zolpidem tablets must be stored at Controlled Room Temperature, specifically defined as 68 F to 77 F (20 C to 25 C). The medication should be kept in the original container and must be tightly closed to protect it from excessive heat, light, and moisture. Due to its classification as a federally controlled substance, the product must be stored out of the reach of children and in a safe place to prevent misuse.

Storage Classification Requirement
Temperature Controlled Room Temperature (20 C to 25 C)
Container Original container, kept tightly closed

For disposal, the safest and preferred method is an authorized drug take-back program or mail-back envelope. If take-back is unavailable, the FDA recommends mixing the tablets with an unappealing substance like dirt or coffee grounds, sealing the mixture in a container, and discarding it in the household trash. Do not flush the tablets down the toilet unless the product labeling specifically instructs it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zolpidem Orifarm found in:

A-Z Index: